238 related articles for article (PubMed ID: 25253630)
1. Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain.
Ostermann H; Solano C; Jarque I; Garcia-Vidal C; Gao X; Barrueta JA; De Salas-Cansado M; Stephens J; Xue M; Weber B; Charbonneau C
BMC Pharmacol Toxicol; 2014 Sep; 15():52. PubMed ID: 25253630
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
[TBL] [Abstract][Full Text] [Related]
3. Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand?
Garbino J; Schnetzler G; Roberts C
Swiss Med Wkly; 2006 Sep; 136(39-40):624-30. PubMed ID: 17086508
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain.
Domínguez-Gil A; Martín I; García Vargas M; Del Castillo A; Díaz S; Sánchez C
Clin Drug Investig; 2007; 27(3):197-205. PubMed ID: 17305414
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia.
Collins CD; Stuntebeck ER; DePestel DD; Stevenson JG
Clin Drug Investig; 2007; 27(4):233-41. PubMed ID: 17358095
[TBL] [Abstract][Full Text] [Related]
8. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
Jørgensen KJ; Gøtzsche PC; Dalbøge CS; Johansen HK
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD004707. PubMed ID: 24563222
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.
Wenzel R; Del Favero A; Kibbler C; Rogers T; Rotstein C; Mauskopf J; Morris S; Schlamm H; Troke P; Marciniak A
J Antimicrob Chemother; 2005 Mar; 55(3):352-61. PubMed ID: 15728146
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands.
Jansen JP; Meis JF; Blijlevens NM; van't Wout JW
Curr Med Res Opin; 2005 Oct; 21(10):1535-46. PubMed ID: 16238893
[TBL] [Abstract][Full Text] [Related]
13. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis.
Lewis JS; Boucher HW; Lubowski TJ; Ambegaonkar AJ; Day DL; Patterson TF
Pharmacotherapy; 2005 Jun; 25(6):839-46. PubMed ID: 15927903
[TBL] [Abstract][Full Text] [Related]
14. Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
Barnes R; Earnshaw S; Herbrecht R; Morrissey O; Slavin M; Bow E; McDade C; Charbonneau C; Weinstein D; Kantecki M; Schlamm H; Maertens J
Clin Ther; 2015 Jun; 37(6):1317-1328.e2. PubMed ID: 25891805
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis.
Harrington R; Lee E; Yang H; Wei J; Messali A; Azie N; Wu EQ; Spalding J
Adv Ther; 2017 Jan; 34(1):207-220. PubMed ID: 27913989
[TBL] [Abstract][Full Text] [Related]
16. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.
Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS
Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy.
Stam WB; Aversa F; Kumar RN; Jansen JP
Value Health; 2008; 11(5):830-41. PubMed ID: 18494752
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole versus amphotericin B in cancer patients with neutropenia.
Jørgensen KJ; Gøtzsche PC; Johansen HK
Cochrane Database Syst Rev; 2006 Jan; (1):CD004707. PubMed ID: 16437492
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain.
Azanza JR; Grau S; Vázquez L; Rebollo P; Peral C; López-Ibáñez de Aldecoa A; López-Gómez V
Mycoses; 2021 Jan; 64(1):66-77. PubMed ID: 32989796
[TBL] [Abstract][Full Text] [Related]
20. Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis.
Greene RE; Mauskopf J; Roberts CS; Zyczynski T; Schlamm HT
Am J Health Syst Pharm; 2007 Dec; 64(24):2561-8. PubMed ID: 18056944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
